Yttrium-90 radioembolization for unresectable liver metastases of melanoma: efficacy and safety / 中华肝胆外科杂志

ABSTRACT

Studies correlated with yttrium-90 (90Y) radioembolization for unresectable liver metastases of melanoma (LMM) were analyzed during January 1st, 1991 to September 1st, 2018. A total of 9 reports involving 207 patients were included for the analysis. The most common primary site of melanoma was choroid, followed by cutaneous and rectal. A total of 199 cases were followed-up, and in 181 patient the complete response rate was 1.1%(2/181), partial response rate was 18.2%(33/181), stable disease rate was 46.4%(84/181), and cancer control rate was 65.7%(119/181). The median survival was 10 months. Complications were found in 42 cases (21.5%, 42/195), including radioembolization induced liver disease (n=39), gastric ulceration (n=2), cholecystitis (n=1), and liver failure (n=3). Adverse reaction included fatigue (14.3%~44.0%), nausea (6.3%~23.0%), and abdominal pain (7.0%~38.0%). 90Y radioembolization is a promising alternative therapy for the treatment of unresectable LMM, with encouraging effects on disease control and survival. Some complications can occur, and adverse reaction are frequent but mild.